Core Viewpoint - The company, Fuhong Hanlin, has seen a significant stock price increase following the announcement of a licensing agreement for its PD-1 monoclonal antibody, Hanshu (Surulitinib), with Eizai in Japan, indicating positive market sentiment towards the deal [1] Group 1: Licensing Agreement Details - Fuhong Hanlin announced that it will license the rights of its PD-1 monoclonal antibody, Hanshu, to Eizai in Japan [1] - Eizai will pay an upfront fee of $75 million to Fuhong Hanlin, along with potential regulatory milestone payments of up to $80.01 million and sales milestone payments of up to $233.3 million [1] - Additionally, Fuhong Hanlin will receive a double-digit percentage royalty based on product sales [1] Group 2: Product Information - Surulitinib is an innovative PD-1 monoclonal antibody developed by Fuhong Hanlin [1] - In China, Surulitinib has been approved for multiple indications, including squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsqNSCLC), and esophageal squamous cell carcinoma (ESCC) [1] - In the European Union, Surulitinib has been approved for the ES-SCLC indication and is the first PD-1 monoclonal antibody approved for first-line treatment of ES-SCLC globally [1]
复宏汉霖早盘涨超5% 公司将汉斯状日本权益授权给卫材 交易总额约3.88亿美元